EP1753435A1 - Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament - Google Patents
Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicamentInfo
- Publication number
- EP1753435A1 EP1753435A1 EP05763426A EP05763426A EP1753435A1 EP 1753435 A1 EP1753435 A1 EP 1753435A1 EP 05763426 A EP05763426 A EP 05763426A EP 05763426 A EP05763426 A EP 05763426A EP 1753435 A1 EP1753435 A1 EP 1753435A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hormone
- combination
- use according
- daily units
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Definitions
- the present invention relates to the use of a combination of ethinylestradiol and chlormadinone acetate for the manufacture of a medicament contemporaneously for the treatment of androgen induced disorders and for hormone replacement therapy and for the treatment of dysmenorrhoea and menstrual stabilization and for the treatment of menstrual cycle related disorders and contraception
- EP-A-0 398 460 is already a hormonal combination preparation for. Treatment of some of these complaints, especially in the pre- or perimenopause and described with a reliable contraceptive protection.
- This preparation is suitable for women who suffer from high blood pressure, as the progestin component acts against it.
- This object is achieved by the use of a combination of ethinylestradiol and chlormadinone acetate for the manufacture of a medicament contemporaneously for the treatment of androgen induced disorders and hormone replacement therapy and for the treatment of dysmenorrhea and menstrual stabilization and for the treatment of menstrual cycle related disorders and contraception used in women, solved.
- a hormone replacement therapy especially for the treatment of vasomotor symptoms, especially in the pre- and perimenopause, such as hot flashes, sweating and / or insomnia
- Dysmenorrhea and menstrual disorders especially premenstrual syndrome, often associated with headache and / or migraine.
- the progestin chlormadinone acetate used in the hormone combination is also particularly suitable for combating menstrual disorders, in particular premenstrual syndrome and associated headaches and / or migraine, and for the treatment of dysmenorrhoea.
- the drug comprising a combination of ethinylestradiol and chlormadinone acetate is also particularly suitable because of the broad spectrum of efficacy listed above for the treatment of women over the age of 35 years, preferably of women in pre- and perimenopause with the mentioned complaints in addition to effective contraception.
- the medicament used according to the invention is preferably formulated in the form of tablets.
- it will be especially in the form of at least 21 hormone-containing daily units that become an uninterrupted, oral Intake are thought to be provided, optionally in combination with 7 to 3 hormone-free daily units.
- the drug in the form of hormone-containing daily units for continuous administration over several years, preferably up to 2 years, more preferably up to one year, optionally in combination with 7 bis 3 hormone-free daily units are provided.
- the medicament prepared according to the invention can also be administered in a dosage form containing less than 365 hormone-containing daily units, such as, for example, B. with 77 to 193 or 42 to 52 hormone-containing daily units for uninterrupted administration, optionally in combination with 7 to 3 hormone-free daily units are prepared.
- 365 hormone-containing daily units such as, for example, B. with 77 to 193 or 42 to 52 hormone-containing daily units for uninterrupted administration, optionally in combination with 7 to 3 hormone-free daily units are prepared.
- the oral dosage form containing the above-listed hormone-containing daily units and the optional hormone-free daily units may also be present as a kit comprising several of these dosage forms for continued use interrupted by the intake of hormone-free daily units or a corresponding intake break.
- each of the hormone-containing daily units has the same amount of ethinyl estradiol or chlormadinone acetate, i. H. both the amount of ethinylestradiol and chlormadinone acetate is kept constant over a single intake cycle.
- the hormone-containing daily units according to a 2-phase or 3-phase intake cycle over a period of 21 to 25 days in their content of ethinylestradiol or chlormadinone acetate in a known manner.
- a process for the preparation of a medicament comprising the hormone combination of ethinylestradiol and chlormadinone acetate and corresponding formulation processes for producing a dosage form, preferably an oral dosage form in the form of tablets, are known to the person skilled in the art.
- Ethinylestradiol (EE) and povidone K 30 (polyvinylpyrrolidone, PVP) were dissolved in 600 ml of ethanol. Chlormadinone acetate (particle size 90% ⁇ 50 microns), lactose and corn starch were mixed in a mixer / granulator (Diosna P25) for 5 min and then moistened with the ethanolic EE / PVP solution and mixed. The wet mass was forced through a 3 mm sieve and dried in a vacuum oven. The dry granules were deagglomerated through a 0.6 mm sieve, mixed with magnesium stearate and fumed silica and pressed on a tablet press with 5 mm punches into 50 mg tablets.
- the tablets were coated with a methylhydroxypropylcellulose-based varnish (e.g., Opadr YS-1-2184); Coating mass 2 mg per tablet.
- a methylhydroxypropylcellulose-based varnish e.g., Opadr YS-1-2184
- Example 2 Composition Per Tablet
- Ethinylestradiol (EE) and povidone K 30 (PVP) were dissolved in 600 ml of ethanol.
- Chlormadinone acetate (particle size 90% ⁇ 50 microns), lactose and corn starch were mixed in a mixer / granulator (Diosna P25) for 5 min and then moistened with the ethanolic EE / PVP solution and mixed.
- the wet mass was forced through a 3 mm sieve and dried in a vacuum oven.
- the dry granules were deagglomerated through a 0.6 mm sieve, mixed with magnesium stearate and fumed silica and pressed on a tablet press with 5 mm punches into tablets weighing 50 mg.
- the tablets were coated with a methylhydroxypropylcellulose-based lacquer having the following composition (coating composition 2 mg per tablet): methylhydroxypropylcellulose 6 mPa ⁇ s, 0.1351 kg
- Example 3 Composition per tablet
- Ethinylestradiol (EE) and povidone K 30 (PVP) were dissolved in 950 ml of ethanol.
- Chlormadinone acetate (particle size 90% ⁇ 50 microns), lactose and corn starch were mixed in a mixer / granulator (Diosna P25) for 5 min and then moistened with the ethanolic EE / PVP solution and mixed.
- the wet mass was forced through a 3 mm sieve and dried in a vacuum oven.
- the dry granules were deagglomerated through a 0.6 mm sieve, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets weighing 80 mg.
- the tablets were coated with a coating based on methylhydroxypropylcellulose having a composition according to Example 2 (coating composition 2 mg per tablet)
- Ethinylestradiol (EE) and povidone K 30 (PVP) were dissolved in 950 ml of ethanol.
- Chlormadinone acetate (particle size 90% ⁇ 50 microns), lactose and corn starch were mixed in a mixer / granulator (Diosna P25) for 5 min and then moistened with the ethanolic EE / PVP solution and mixed.
- the wet mass was forced through a 3 mm sieve and dried in a vacuum oven.
- the dry granules were deagglomerated through a 0.6 mm sieve, mixed with magnesium stearate and pressed on a tablet press with 6 mm punches into tablets weighing 80 mg.
- the tablets were coated with a methylhydroxypropylcellulose-based lacquer having the following composition (coating composition 1 mg per tablet) of methylhydroxypropylcellulose 6 mPa ⁇ s, 0.068 kg
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004026669A DE102004026669A1 (en) | 2004-05-28 | 2004-05-28 | Use of a combination of ethinylestradiol and chlormadinone acetate for the manufacture of a medicament |
PCT/EP2005/005764 WO2005115402A1 (en) | 2004-05-28 | 2005-05-27 | Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1753435A1 true EP1753435A1 (en) | 2007-02-21 |
Family
ID=34982562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05763426A Ceased EP1753435A1 (en) | 2004-05-28 | 2005-05-27 | Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050267081A1 (en) |
EP (1) | EP1753435A1 (en) |
AR (1) | AR049195A1 (en) |
AU (1) | AU2005247101B2 (en) |
BR (1) | BRPI0511864A (en) |
DE (1) | DE102004026669A1 (en) |
EC (1) | ECSP067030A (en) |
MX (1) | MXPA06013800A (en) |
PE (1) | PE20060402A1 (en) |
RU (1) | RU2394579C2 (en) |
WO (1) | WO2005115402A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004026671A1 (en) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Dosage form for hormonal contraception |
DE102006003508A1 (en) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Use of hormone combination of estrogen from ethinyl estradiol and metabolites of chlormadinone acetate, with chlormadione acetate as gestagen components, for producing medicament e.g. for preventing menstruation cycle-dependent mood |
DE102006003509A1 (en) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Drug delivery system, for hormonal contraception, comprises hormone-containing daily unit, which exhibits estrogen from ethinyl estradiol and estradiol and from metabolite of the chlormadinone acetate optionally with gestagen component |
DE102006062119A1 (en) * | 2006-12-22 | 2008-06-26 | Grünenthal GmbH | Medicines for the treatment of skin diseases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
AU4805085A (en) * | 1984-09-05 | 1986-03-24 | Schering Aktiengesellschaft | Mittel zur behandlung von androgenisierungserscheinungen und verwendung von antiandrogenen zur herstellung des mittels |
DE19525017A1 (en) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmaceutical combination preparation, kit and method for hormonal contraception |
US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
DE19739916C2 (en) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands |
US6326392B1 (en) * | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
CN1644201A (en) * | 1998-04-17 | 2005-07-27 | 奥索-麦克尼尔药品公司 | Application of folic acid-containing pharmaceutical compositions |
US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
DE10045380A1 (en) * | 2000-09-14 | 2002-04-04 | Schering Ag | Contraception procedure and dosage form |
US8048869B2 (en) * | 2001-05-18 | 2011-11-01 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
CN101099734A (en) * | 2002-08-15 | 2008-01-09 | 惠氏公司 | Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction |
US7772219B2 (en) * | 2003-05-02 | 2010-08-10 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
-
2004
- 2004-05-28 DE DE102004026669A patent/DE102004026669A1/en not_active Withdrawn
- 2004-12-10 US US11/009,361 patent/US20050267081A1/en not_active Abandoned
-
2005
- 2005-05-27 WO PCT/EP2005/005764 patent/WO2005115402A1/en active Application Filing
- 2005-05-27 AR ARP050102211A patent/AR049195A1/en unknown
- 2005-05-27 RU RU2006145077/15A patent/RU2394579C2/en active
- 2005-05-27 MX MXPA06013800A patent/MXPA06013800A/en active IP Right Grant
- 2005-05-27 AU AU2005247101A patent/AU2005247101B2/en active Active
- 2005-05-27 EP EP05763426A patent/EP1753435A1/en not_active Ceased
- 2005-05-27 BR BRPI0511864-6A patent/BRPI0511864A/en not_active Application Discontinuation
- 2005-05-27 PE PE2005000595A patent/PE20060402A1/en not_active Application Discontinuation
-
2006
- 2006-11-27 EC EC2006007030A patent/ECSP067030A/en unknown
Non-Patent Citations (1)
Title |
---|
BRUCKER C ET AL: "Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen", CONTRACEPTION, GERON-X, INC., LOS ALTOS, CA, US, vol. 81, no. 6, 1 June 2010 (2010-06-01), pages 501 - 509, XP027049307, ISSN: 0010-7824, [retrieved on 20100219] * |
Also Published As
Publication number | Publication date |
---|---|
RU2394579C2 (en) | 2010-07-20 |
DE102004026669A1 (en) | 2005-12-15 |
PE20060402A1 (en) | 2006-07-12 |
MXPA06013800A (en) | 2007-02-02 |
BRPI0511864A (en) | 2008-01-22 |
WO2005115402A1 (en) | 2005-12-08 |
US20050267081A1 (en) | 2005-12-01 |
AU2005247101A1 (en) | 2005-12-08 |
AR049195A1 (en) | 2006-07-05 |
AU2005247101B2 (en) | 2011-02-17 |
ECSP067030A (en) | 2006-12-29 |
RU2006145077A (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0499348B1 (en) | Ovulation-inhibiting agent for hormonal contraception | |
DE19739916C2 (en) | Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands | |
EP2131847B1 (en) | Drug comprising at least one gestagen | |
EP1753408B1 (en) | Hormonal contraceptive containing a combination of ethinyl estradiol and chlormadinone acetate | |
WO1998035682A1 (en) | Agent for hormonal contraception and/or treatment and/or prophylaxis of mammary glands with three hormone components | |
DE60203929T2 (en) | TREATMENT PROCEDURE AND PHARMACEUTICAL COMPOSITION FOR EMERGENCY CONSUMER PREVENTION | |
WO2010089078A1 (en) | Buccal application system comprising 17α-estradiol | |
EP1758560B1 (en) | Hormonal composition containing a combination of ethinyl estradiol and chlormadinone acetate | |
DE4224534A1 (en) | Anti-ovulation agent for hormonal contraception | |
EP1753435A1 (en) | Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament | |
EP1978970B1 (en) | Contraceptive | |
EP1978969B1 (en) | Hormone combination for alleviation of menstrual cycle dependent mood fluctuations | |
EP2749278A1 (en) | Gestagen combination and an insulin sensitizer for treating PCOS | |
EP2229154B1 (en) | Pharmaceutical containing a hormone combination having a contraceptive effect and an insulin sensitizer | |
EP1853273A1 (en) | Pharmaceutical composition for contraception | |
DE102005056527A1 (en) | Use of a combination of ethinylestradiol and chlormadinone acetate for the manufacture of a medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061228 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: LV |
|
RAX | Requested extension states of the european patent have changed |
Extension state: LV Payment date: 20061228 |
|
17Q | First examination report despatched |
Effective date: 20080731 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RICHTER GEDEON NYRT. |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAV | Appeal reference deleted |
Free format text: ORIGINAL CODE: EPIDOSDREFNE |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20180620 |